Key result
Histologic response to preoperative chemotherapy strongly predicted 10-year disease-free survival in Stage IIB osteogenic sarcoma, with 90% survival for complete versus 54% for little response.
Why the study?
What are the long-term survival outcomes and prognostic factors in patients with Stage IIB osteogenic sarcoma?
Population
271 consecutive patients with Stage IIB Osteogenic Sarcoma treated from 1976 through 1986
Design
Cohort
Follow-up
10 years
Authors
Loading...
Histologic response may refine prognosis after chemotherapy for bone sarcomas; leaves open whether it should guide modern treatment adaptation.
Cohort (n=271)
What are the long-term survival outcomes and prognostic factors in patients with Stage IIB osteogenic sarcoma?
Absolute Event Rate: 90% vs 54%
In patients with Stage IIB osteogenic sarcoma, histologic response to preoperative chemotherapy is the strongest predictor of long-term disease-free survival.
Glasser et al. (1991) conducted a cohort in Stage IIB Osteogenic Sarcoma (n=271). Histologic response to preoperative chemotherapy vs. Little response was evaluated on Disease-free survival at 10 years. Histologic response to preoperative chemotherapy strongly predicted 10-year disease-free survival in Stage IIB osteogenic sarcoma, with 90% survival for complete versus 54% for little response.